Clinical trials: Coagulation Protein Disorders
Hemophilia A
Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity
Hemophilia A is a rare X chromosome-linked recessive bleeding disorder that concerns one individual in 5000. In its severe form, hemophilia A is a life-threatening, crippling hemorrhagic disease.
- Trial name
- SOLUCLOT (NCT02911233)
- Testing
- Thromboelastograpgy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Caen
Hemophilia B
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
The purpose of this study is to determine the safety of giving a normal factor IX gene to treat individuals who have an abnormal or no factor IX gene.
- Trial name
- NCT00979238
- Testing
- Gene Transfer, scAAV2/8-LP1-hFIXco
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
Coagulation Disorder
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
A single centre, open-label study to assess the effects of VMX-C001 in combination with an oral FXa DOAC on the efficacy of Unfractionated Heparin (UFH) and of VMX-C001 alone on the efficacy of Low Molecular Weight Heparin (LMWH)…
- Trial name
- NCT06517563
- Testing
- VMX-C001, Rivaroxaban, UFH
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Factor X Deficiency
Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery
To primary efficacy variable is to assess the presence or absence of excessive blood loss during and after surgery. The secondary efficacy endpoints are as follows: 1.
- Trial name
- Ten03 (NCT01086852)
- Testing
- FACTOR X
- Where
- 7 sites in United States, Spain and 2 more
- Volunteers
- 4 people
- Sponsor
- Bio Products Laboratory
vonWillebrand Disease, Hemophilia
The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders
The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments.
- Conditions
- vonWillebrand Disease, Hemophilia, Platelet Coagulation Disorders
- Trial name
- NCT00697385
- Testing
- Cyclokapron
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mary M. Gooley Hemophilia Center
Severe Hemophilia A
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
To evaluate the prophylactic efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A.
- Trial name
- NCT06142552
- Testing
- FRSW117
- Where
- 28 sites in China
- Volunteers
- 124 people
- Sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Hemophilia A, Hemophilia B
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Primary Objective: -To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes.
- Trial name
- NCT03417245
- Testing
- fitusiran, factor concentrates
- Where
- 64 sites in United States, Australia and 17 more
- Volunteers
- 120 people
- Sponsor
- Genzyme, a Sanofi Company
Haemophilia
Evaluation of Xylitol Wipes as an Oral Hygiene Protocol for Haemophilic Children
The purpose of this study is to evaluate xylitol wipes as an oral hygiene protocol for haemophilic children
- Trial name
- NCT05899075
- Testing
- xylitol wipes
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Al-Azhar University
Trauma, Bleeding Disorder
Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial
This is a randomized feasibility trial conducted with severe trauma patients. At admission patients presented hypofibrinogenemia, hypotension and tachycardia.
- Conditions
- Trauma, Bleeding Disorder, Fibrinogen; Deficiency, Acquired
- Trial name
- NCT02864875
- Testing
- Fibrinogen concentrate
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- University of Sao Paulo General Hospital
Severe Hemophilia A
Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)
The purpose of the study is to study the long-term efficacy, safety and tolerability of Human-cl rhFVIII in previously treated patients with severe hemophilia A.
- Trial name
- NCT01341912
- Testing
- Human-cl rhFVIII
- Where
- 2 sites in United States, Bulgaria
- Volunteers
- 3 people
- Sponsor
- Octapharma
Hemophilia
MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II
MOTHIF II is a non-interventional, multicenter, retrospective, observational data collection in seven French Haemophilia Treatment Centers of the BERHLINGO network.
- Trial name
- MOTHIF II (NCT03596814)
- Testing
- No Interventional study
- Where
- 7 sites in France
- Volunteers
- 2,072 people
- Sponsor
- Nantes University Hospital
Von Willebrand Disease
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of…
- Trial name
- OPALE (NCT04657887)
- Testing
- Voncento®
- Where
- 17 sites in France
- Volunteers
- 135 people
- Sponsor
- CSL Behring
Hemophilia A
Goal Attainment and Physical Activity in People With Hemophilia A
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan.
- Trial name
- ACTIVIIITY (NCT06530030)
- Testing
- efanesoctocog alfa
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sanofi
Hemophilia A
The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
A non-randomized, open-label, dose-escalation study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS802 in hemophilia A subjects with endogenous FVIII ≤2%.
- Trial name
- NCT05523128
- Testing
- ZS802
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Congenital Bleeding Disorder, Haemophilia A
Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (how the trial drug is distributed in the body) of NNC172-2021 administered subcutaneously, at two different dose levels, in healthy…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B, Healthy
- Trial name
- NCT01555749
- Testing
- NNC172-2021
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Von Willebrand Disease
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
Von Willebrand disease is an inherited bleeding disorder that impacts the blood's ability to clot properly. Von Willebrand disease is cause by the lack or not working substance in the blood known as Von Willebrand factor.
- Trial name
- NCT00630448
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
- Trial name
- NCT00525447
- Testing
- SGN-40, lenalidomide, dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Seagen Inc.
Thrombosis
Thrombus Formation Under Different Flow-conditions
Rationale: Cardiovascular diseases are important causes of morbidity and mortality in the industrialized world. Clinical studies indicate an important role for the proteins of the contact activation system (coagulation factor XII…
- Trial name
- NCT01114074
- Where
- Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Hemophilia A, Severe Hemophilia A
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
This multicenter, open-label, phase 3 extension study will investigate the safety and efficacy of rVIII-SingleChain for prophylaxis and on-demand treatment of bleeding episodes in at least 200 previously treated patients (PTPs)…
- Trial name
- NCT02172950
- Testing
- rVIII-SingleChain
- Where
- 64 sites in United States, Australia and 23 more
- Volunteers
- 246 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.